1.Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease.
Han-Rong FENG ; Chao ZHANG ; Song-Min YING
Chinese Medical Journal 2018;131(16):1894-1897
Air Pollution
;
Antibodies, Monoclonal, Humanized
;
therapeutic use
;
Humans
;
Lung
;
drug effects
;
metabolism
;
Models, Biological
;
Parenchymal Tissue
;
drug effects
;
metabolism
;
Phosphodiesterase 4 Inhibitors
;
therapeutic use
;
Pulmonary Disease, Chronic Obstructive
;
drug therapy
;
metabolism
;
World Health Organization
2.Efficacy and Safety of Roflumilast in Korean Patients with COPD.
Jae Seung LEE ; Yoon Ki HONG ; Tae Sun PARK ; Sei Won LEE ; Yeon Mok OH ; Sang Do LEE
Yonsei Medical Journal 2016;57(4):928-935
PURPOSE: Roflumilast is the only oral phosphodiesterase 4 inhibitor approved to treat chronic obstructive pulmonary disease (COPD) patients [post-bronchodilator forced expiratory volume in 1 second (FEV1) <50% predicted] with chronic bronchitis and a history of frequent exacerbations. This study evaluated the efficacy and safety of roflumilast in Korean patients with COPD and compared the efficacy based on the severity of airflow limitation. MATERIALS AND METHODS: A post-hoc subgroup analysis was performed in Korean COPD patients participating in JADE, a 12-week, double-blinded, placebo-controlled, parallel-group, phase III trial in Asia. The primary efficacy endpoint was the mean [least-squares mean adjusted for covariates (LSMean)] change in post-bronchodilator FEV1 from baseline to each post-randomization visit. Safety endpoints included adverse events (AEs) and changes in laboratory values, vital signs, and electrocardiograms. RESULTS: A total of 260 Korean COPD patients were recruited, of which 207 were randomized to roflumilast (n=102) or placebo (n=105) treatment. After 12 weeks, LSMean post-bronchodilator FEV1 increased by 43 mL for patients receiving roflumilast and decreased by 60 mL for those taking placebo. Adverse events were more common in the roflumilast group than in the placebo group; however, the types and frequency of AEs were comparable to those reported in previous studies. CONCLUSION: Roflumilast significantly improved lung function with a tolerable safety profile in Korean COPD patients irrespective of the severity of airflow limitation.
Aged
;
Aminopyridines/*therapeutic use
;
*Asian Continental Ancestry Group
;
Benzamides/*therapeutic use
;
Cyclopropanes/therapeutic use
;
Double-Blind Method
;
Female
;
Humans
;
Male
;
Middle Aged
;
Phosphodiesterase 4 Inhibitors/*therapeutic use
;
Pulmonary Disease, Chronic Obstructive/*drug therapy/*ethnology/physiopathology
;
Republic of Korea
;
Respiratory Function Tests
;
Treatment Outcome
3.Effects of phosphodiesterase 4 inhibitor on cough response in guinea pigs sensitized and challenged with ovalbumin.
Han-Jing LÜ ; Zhong-Min QIU ; Wei-Li WEI ; Li YU ; Rui-Lin LIU ; Min ZHANG
Chinese Medical Journal 2004;117(11):1620-1624
BACKGROUNDThere is currently considerable interest in the potential value of selective inhibitors of cyclic nucleotide phosphodiesterase 4 in the treatment of asthma. However, whether they influence eosinophilic airway inflammation-associated cough remains unclear. The objective of this study was to investigate the effects of selective phosphodiesterase 4 inhibitor SB207499 on cough response and airway inflammation in guinea pigs sensitized and challenged with ovalbumin.
METHODSForty sensitized guinea pigs were randomly divided into four groups: control (n = 10), challenge (n = 10), SB207499 (n = 10) and aminophylline (n = 10), then challenged with aerosol of 1% ovalbumin or saline. Two hours later, animals were intraperitoneally injected with either saline, 25 mg/kg of SB207499 or aminophylline. At the 24th hour, the injection was repeated with 2.5 mg/kg and 25 mg/kg SB207499 or aminophylline, then cough response to inhaled capsaicin and airway responsiveness to methacholine inducing a 150% of the peak airway pressure to the baseline (PC150) was measured. Finally, total cell number and differentials in bronchoalveolar lavage fluid were analysed.
RESULTSThe cough frequency per 3 minutes and PC150 in the challenge group were (22 +/- 4) times/3 minutes and (198 +/- 54) microg/ml, which were significantly different from (6 +/- 2) times/3 minutes and (691 +/- 81) microg/ml in the control group (P < 0.05, respectively). The injection of 25 mg/kg SB207499 significantly inhibited the increased cough response and airway hyperresponsiveness, the cough frequency and PC150 in guinea pigs were (13 +/- 2) times/3 minutes and (680 +/- 81) microg/ml (P < 0.05), which differed significantly from (18 +/- 2) times/3 minutes and (400 +/- 86) microg/ml after the administration of the same dose of aminophylline (P < 0.05). The inhibition of SB207499 on cough response was dose-dependent. Similarly, SB207499 decreased the total cell number and percentage of eosinophils in bronchoalveolar lavage fluid to (2.1 +/- 0.5) x 10(6)/ml and (20 +/- 5)% respectively, which were significantly different from (3.2 +/- 0.5) x 10(6)/ml and (29 +/- 5)% in the aminophylline group (P < 0.05, respectively) or (4.2 +/- 0.7) x 10(6)/ml and (35 +/- 4)% in the challenge group (P < 0.05, respectively).
CONCLUSIONPhosphodiesterase 4 inhibitor may be more useful than aminophylline for cough associated with eosinophilic airway inflammation via inhibiting airway inflammation and airway hyperresponsiveness.
3',5'-Cyclic-AMP Phosphodiesterases ; antagonists & inhibitors ; Animals ; Bronchial Hyperreactivity ; drug therapy ; Bronchoalveolar Lavage Fluid ; cytology ; Cough ; drug therapy ; Cyclic AMP ; biosynthesis ; Cyclic Nucleotide Phosphodiesterases, Type 4 ; Cyclohexanecarboxylic Acids ; therapeutic use ; Dose-Response Relationship, Drug ; Guinea Pigs ; Male ; Nitriles ; Ovalbumin ; immunology ; Phosphodiesterase Inhibitors ; therapeutic use